However, despite the fact that there is a significant amount of clinical evidence suggesting a net cardiovascular benefit with GLP-1 receptor agonists use in DM, mainly driven by the reduction in ASCVD events, underlying mechanisms are not yet fully understood. Here, GLP1R is linked to atherosclerosis.